ABSTRACT
The female reproductive tract (FRT) is a complex environment, rich in mucin glycoproteins that form a dense network on the surface of the underlying epithelia. Group B Streptococcus (GBS) asymptomatically colonizes 25–30% of healthy women, but during pregnancy can cause ascending infection in utero or be transmitted to the newborn during birth to cause invasive disease. Though the cervicovaginal mucosa is a natural site for GBS colonization, the specific interactions between GBS and mucins remain unknown. Here we demonstrate for the first time that MUC5B interacts directly with GBS and promotes barrier function by inhibiting both bacterial attachment to human epithelial cells and ascension from the vagina to the uterus in a murine model of GBS colonization. RNA sequencing analysis of GBS exposed to MUC5B identified 128 differentially expressed GBS genes, including upregulation of the pilus island-2b (PI-2b) locus. We subsequently show that PI-2b is important for GBS attachment to reproductive cells, binding to immobilized mucins, and vaginal colonization in vivo. Our results suggest that while MUC5B plays an important role in host defense, GBS upregulates pili in response to mucins to help promote persistence within the vaginal tract, illustrating the dynamic interplay between pathogen and host.
KEYWORDS: mucin, pili, vaginal colonization
OBSERVATION
The thick apical glycocalyx covering the epithelium of the FRT is primarily composed of mucin glycoproteins (1). Mucins can be attached to epithelial cell surfaces or released as gel-forming polymers into luminal spaces, and are characterized by large, filamentous protein domains extensively decorated with O-glycosidic linked short-chain glycans (2). In the FRT, the main cell surface associated mucins are MUC1 and MUC4, and the predominant secreted polymeric mucins are MUC5B and MUC5AC. Group B Streptococcus (GBS) is a Gram-positive bacterium that asymptomatically colonizes the FRT; however, during pregnancy GBS can cause intrauterine infection, premature rupture of membranes (PROM), and preterm birth (3, 4). GBS can also be transmitted to the fetus or newborn resulting in serious invasive infections such as pneumonia, sepsis, and meningitis (3). Though the cervicovaginal mucosa is a natural site for GBS colonization, the interactions between GBS and mucins have not been studied previously.
MUC5B-GBS interactions.
To understand how mucins impact GBS colonization, we assessed GBS adherence to human vaginal epithelial cells in the presence of MUC5B and found that as low as 0.03% MUC5B inhibited bacterial attachment to vaginal cells (Fig. 1A, Fig. S1A in the supplemental material). To examine this interaction in vivo, we utilized a murine model of GBS vaginal colonization (5) and observed a significant decrease in recovered GBS from the vaginal lumen of Muc5B−/− mice (6) compared to wild-type (WT) mice (Fig. 1B). Despite this, there was increased GBS ascension from the vaginal lumen to the uterus in Muc5B−/− mice, with a positive ascension Spearman correlation in Muc5B−/− mice (P = 0.0167) that was absent in WT mice (P = 0.1361) (Fig. 1C, Fig. S1B). These results suggest that mucins localize GBS in the vaginal lumen and limit GBS ascension. Future studies on how the microbiome and immunologic differences in Muc5B−/− mice may contribute to GBS ascension will be of interest.
We next visualized GBS in the presence of MUC5B by confocal microscopy. GBS grew homogenously through the column of control medium samples (Fig. 1D and F), while GBS grown in the presence of natively purified MUC5B mucins was heterogeneously distributed and formed aggregated structures with marked furrows throughout (Fig. 1E and F), suggesting that mucins agglutinate GBS, which could decrease interactions at the epithelial surface. Similar mechanisms of mucin-mediated agglutination have been characterized in oral Streptococci, where mucins aggregate bacteria to facilitate clearance by swallowing or enhancing phagocytosis (7). We further observed that GBS binds directly to immobilized mucins compared to untreated or 1% BSA control coated wells (Fig. 1G). While others have shown mucins can inhibit biofilm formation by some opportunistic pathogens (8–10), we observed that GBS grown in the presence of MUC5B formed larger aggregates compared to those grown in control medium alone and the addition of mucins did not impact bacterial growth (Fig. S1C–F).
MUC5B modulates the GBS transcriptome.
To determine the GBS response to mucins, we performed RNA sequencing analyses of GBS grown with MUC5B and identified 128 differentially expressed genes including 87 upregulated and 41 downregulated genes (Fig. 2A, Table S1). Clusters of orthologous proteins (COGs) were identified for 63 upregulated and 37 downregulated genes (Fig. 2B). The most abundant upregulated COGs were involved in carbohydrate transport/metabolism (24/63, 38%), suggesting signaling could occur via the carbohydrate moieties on the mucin polymers. Many bacterial species possess mucolytic enzymes that can release and metabolize sugars from the mucin backbone (11, 12), and examples have been primarily described in organisms isolated from the human gastrointestinal tract (13, 14). While GBS is known to possess trans-sialidases that could contribute to this process, they have not been studied in this context (15). In studies with other opportunistic pathogens, mucin exposure suppressed virulence traits (8–10); however, our analyses revealed an upregulation of GBS virulence factors including the type VII secretion system (T7SS) and the pilus island-2b (PI-2b). The GBS T7SS was recently identified and shown to contribute to invasive disease (16), although its role in vaginal colonization remains to be determined.
PI-2b contributes to mucin interactions and vaginal colonization.
All GBS strains express one or two pili encoded by three different pilus islands, PI-1, PI-2a, or PI-2b (17). The GBS COH1 strain used here is a serotype III, sequence type-17 and encodes pilus islands PI-1 and PI-2b, but only PI-2b was shown to be required for interaction with brain endothelium and lung epithelial cells, as well as the development of invasive disease (17, 18). To characterize the role of PI-2b in GBS mucosal interactions within the FRT, we confirmed differential expression of genes within the PI-2b locus (Fig. 2C) by qRT-PCR following incubation with MUC5B (Fig. 2D). We then determined that GBS lacking the main backbone pilin protein (Δbp-2b) was less adherent than WT GBS to both squamous vaginal epithelial cells and columnar endocervical epithelial cells, and this phenotype was complemented by expression of the bp-2b gene in the Δbp-2b mutant strain (Δbp-2b+bp-2b) (Fig. S1G, H). To examine the role of PI-2b in vivo, mice were inoculated intravaginally with GBS WT and Δbp-2b strains, and bacterial burden within the lumen was monitored over time. We observed a fitness defect in the Δbp-2b mutant in the vaginal tract compared to WT GBS (Fig. 2E). We also observed a significant reduction in mucin binding by the Δbp-2b mutant (Fig. 2F), which is consistent with other studies showing bacterial pili can promote interactions with colonic mucus and salivary glycoproteins (19, 20). These data suggest a key role for PI-2b in facilitating GBS attachment to host mucins and the reproductive epithelium, and persistence within the vaginal mucosa in vivo. Future studies examining the role of PI-2b in GBS tissue colonization and ascension are warranted.
Conclusions.
Here we describe for the first time the dynamic interplay between GBS and host mucins in the FRT. MUC5B induced GBS agglutination, prevented bacterial attachment to epithelial cells, concentrated GBS in the vaginal lumen, and served as a barrier against ascending infection (Fig. 2G). MUC5B also induced GBS virulence factors such as PI-2b that contribute to host cell attachment and FRT colonization. As protein–carbohydrate interactions typically mediate the first step in pathogen colonization, we hypothesize that GBS pili normally bind carbohydrate moieties on the epithelium, which could be outcompeted by glycosylated mucins in this environment, though this warrants further investigation. These initial observations provide a platform for future studies to understand the mechanisms of GBS-reproductive mucosal interactions that could lead to novel interventions to improve maternal–fetal health, reduce adverse pregnancy outcomes, and limit transmission to the newborn.
ACKNOWLEDGMENTS
We thank the BROAD Institute Microbial Omics Core for performing RNA sequencing, Zachary Burcham for help with RNA sequencing analysis, and Maddalena Lazzarin, Daniela Rinaudo, and Immaculada Margarit of GSK, Siena, Italy for providing GBS Δbp-2b mutant and complemented strains. This work was supported by NIH grants R01EB017755-04 to K.R., T32-ES007020 to J.R.B., T32AI052066-19 to L.M.L., and R01NS116716 and R01AI153332 to K.S.D.
Contributor Information
Kelly S. Doran, Email: kelly.doran@cuanschutz.edu.
Nancy E. Freitag, University of Illinois at Chicago
REFERENCES
- 1.Carson DD, DeSouza MM, Kardon R, Zhou X, Lagow E, Julian J. 1998. Mucin expression and function in the female reproductive tract. Hum Reprod Update 4:459–464. doi: 10.1093/humupd/4.5.459. [DOI] [PubMed] [Google Scholar]
- 2.McGuckin MA, Thornton DJ, Whitsett JA. 2015. Mucins and mucus, p 231–250. In Mestecky J, Strober W, Russell MW, Kelsall BL, Cheroutre H, Lambrecht BN (ed), Mucosal immunology (4th ed). Academic Press, Boston, MA. doi: 10.1016/B978-0-12-415847-4.00014-8. [DOI] [Google Scholar]
- 3.Armistead B, Oler E, Waldorf KA, Rajagopal L. 2019. The double life of group B streptococcus: asymptomatic colonizer and potent pathogen. J Mol Biol 431:2914–2931. doi: 10.1016/j.jmb.2019.01.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Allen U, Nimrod C, Macdonald N, Toye B, Stephens D, Marchessault V. 1999. Relationship between antenatal group B streptococcal vaginal colonization and premature labour. Paediatr Child Health 4:465–469. doi: 10.1093/pch/4.7.465. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Patras KA, Doran KS. 2016. A murine model of group B Streptococcus vaginal colonization. JoVE:e54708. doi: 10.3791/54708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, Alexander SN, Bellinghausen LK, Song AS, Petrova YM, Tuvim MJ, Adachi R, Romo I, Bordt AS, Bowden MG, Sisson JH, Woodruff PG, Thornton DJ, Rousseau K, De la Garza MM, Moghaddam SJ, Karmouty-Quintana H, Blackburn MR, Drouin SM, Davis CW, Terrell KA, Grubb BR, O'Neal WK, Flores SC, Cota-Gomez A, Lozupone CA, Donnelly JM, Watson AM, Hennessy CE, Keith RC, Yang IV, Barthel L, Henson PM, Janssen WJ, Schwartz DA, Boucher RC, Dickey BF, Evans CM. 2014. Muc5b is required for airway defence. Nature 505:412–416. doi: 10.1038/nature12807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Itzek A, Chen Z, Merritt J, Kreth J. 2017. Effect of salivary agglutination on oral streptococcal clearance by human polymorphonuclear neutrophil granulocytes. Mol Oral Microbiol 32:197–210. doi: 10.1111/omi.12164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Wheeler KM, Cárcamo-Oyarce G, Turner BS, Dellos-Nolan S, Co JY, Lehoux S, Cummings RD, Wozniak DJ, Ribbeck K. 2019. Mucin glycans attenuate the virulence of Pseudomonas aeruginosa in infection. Nat Microbiol 4:2146–2154. doi: 10.1038/s41564-019-0581-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Werlang CA, Chen WG, Aoki K, Wheeler KM, Tymm C, Mileti CJ, Burgos AC, Kim K, Tiemeyer M, Ribbeck K. 2021. Mucin O-glycans suppress quorum-sensing pathways and genetic transformation in Streptococcus mutans. Nat Microbiol 6:574–583. doi: 10.1038/s41564-021-00876-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Kavanaugh NL, Zhang AQ, Nobile CJ, Johnson AD, Ribbeck K, Berman J. 2014. Mucins suppress virulence traits of Candida albicans. mBio 5:e01911-14. doi: 10.1128/mBio.01911-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Koropatkin NM, Cameron EA, Martens EC. 2012. How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol 10:323–335. doi: 10.1038/nrmicro2746. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Sicard J-F, Le Bihan G, Vogeleer P, Jacques M, Harel J. 2017. Interactions of Intestinal bacteria with components of the intestinal mucus. Front Cell Infect Microbiol 7:387–387. doi: 10.3389/fcimb.2017.00387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Derrien M, Vaughan EE, Plugge CM, de Vos WM. 2004. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 54:1469–1476. doi: 10.1099/ijs.0.02873-0. [DOI] [PubMed] [Google Scholar]
- 14.Bell A, Brunt J, Crost E, Vaux L, Nepravishta R, Owen CD, Latousakis D, Xiao A, Li W, Chen X, Walsh MA, Claesen J, Angulo J, Thomas GH, Juge N. 2019. Elucidation of a sialic acid metabolism pathway in mucus-foraging Ruminococcus gnavus unravels mechanisms of bacterial adaptation to the gut. Nat Microbiol 4:2393–2404. doi: 10.1038/s41564-019-0590-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Tailford LE, Owen CD, Walshaw J, Crost EH, Hardy-Goddard J, Le Gall G, de Vos WM, Taylor GL, Juge N. 2015. Discovery of intramolecular trans-sialidases in human gut microbiota suggests novel mechanisms of mucosal adaptation. Nat Commun 6:7624. doi: 10.1038/ncomms8624. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Spencer BL, Tak U, Mendonça JC, Nagao PE, Niederweis M, Doran KS. 2021. A type VII secretion system in Group B Streptococcus mediates cytotoxicity and virulence. PLoS Pathog 17:e1010121. doi: 10.1371/journal.ppat.1010121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Lazzarin M, Mu R, Fabbrini M, Ghezzo C, Rinaudo CD, Doran KS, Margarit I. 2017. Contribution of pilus type 2b to invasive disease caused by a Streptococcus agalactiae ST-17 strain. BMC Microbiol 17:148. doi: 10.1186/s12866-017-1057-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Périchon B, Guignot J, Szili N, Gao C, Poyart C, Trieu-Cuot P, Dramsi S. 2019. Insights into Streptococcus agalactiae PI-2b pilus biosynthesis and role in adherence to host cells. Microbes Infect 21:99–103. doi: 10.1016/j.micinf.2018.10.004. [DOI] [PubMed] [Google Scholar]
- 19.Martins M, Aymeric L, Du Merle L, Danne C, Robbe-Masselot C, Trieu-Cuot P, Sansonetti P, Dramsi S. 2015. Streptococcus gallolyticus Pil3 pilus is required for adhesion to colonic mucus and for colonization of mouse distal colon. J Infect Dis 212:1646–1655. doi: 10.1093/infdis/jiv307. [DOI] [PubMed] [Google Scholar]
- 20.Brittan JL, Nobbs AH. 2015. Group B Streptococcus pili mediate adherence to salivary glycoproteins. Microbes Infect 17:360–368. doi: 10.1016/j.micinf.2014.12.013. [DOI] [PubMed] [Google Scholar]
- 21.Périchon B, Szili N, Du Merle L, Rosinski-Chupin I, Gominet M, Bellais S, Poyart C, Trieu-Cuot P, Dramsi S. 2017. Regulation of PI-2b pilus expression in hypervirulent Streptococcus agalactiae ST-17 BM110. PLoS One 12:e0169840. doi: 10.1371/journal.pone.0169840. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.